Results 1 to 10 of about 6,478 (160)
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
Antibiotics, 2022 Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related hospitalization or death was observed in patients treated with nirmatrelvir ...
Wen-Chien Ko +2 more
exaly +3 more sources
Infectious Diseases and TherapyIntroduction Limited data exist regarding real-world utilization of nirmatrelvir/ritonavir. We identified predictors of nirmatrelvir/ritonavir use among Veterans Affairs (VA) outpatients nationally. Methods We conducted a retrospective cohort study among
Laura Puzniak +2 more
exaly +2 more sources
Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses
EMBO Molecular Medicine, 2023 Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin‐like cysteine protease—has been shown to reduce the risk of progression to ...
Raffaele De Francesco +2 more
exaly +2 more sources
A Phase 1 Multiple‐Dose, Open‐Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women [PDF]
Clinical and Translational ScienceIn accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir ...
Jacqueline Gerhart +7 more
doaj +2 more sources
Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study [PDF]
Frontiers in MedicineBackgroundPatients with severe or critical coronavirus disease 2019 (COVID-19) remain at a high risk of mortality. Although nirmatrelvir/ritonavir has demonstrated efficacy in non-severe COVID-19 patients with high-risk factors, its effectiveness in ...
Heng Zhao +11 more
doaj +2 more sources
The Remarkable Selectivity of Nirmatrelvir
ACS Pharmacology & Translational Science, 2022 The SARS-CoV-2 main protease is among the most attractive targets for the development of therapeutic interventions for COVID-19. Successful candidate agents will not only possess potent on-target activity versus SARS-CoV-2 Mpro but also minimal polypharmacology versus human cysteine proteases.
Damien Y. Duveau, Craig J. Thomas
openaire +2 more sources
BMC Nephrology, 2023 Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider +5 more
doaj +1 more source
EClinicalMedicine, 2023 Summary: Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/
Jon Salmanton-García +115 more
doaj +1 more source
Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
Разработка и регистрация лекарственных средств, 2023 Introduction. SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) is expected to remain a persistent global threat. Therefore, development of coronavirus disease 2019 (COVID-19) drugs is the most urgent global issue.
T. N. Komarov +7 more
doaj +1 more source
Brazilian Journal of Infectious Diseases, 2023 Introdução: O tratamento com NIRI diminui a taxa de hospitalização em pacientes imunocompetentes com COVID-19, mas os dados sobre a eficácia em pacientes com malignidade hematológica (MH) são escassos.
Jon Salmanton-García +3 more
doaj +1 more source